MAIA Biotechnology is projected to report $0.00 in revenue and a consensus loss of $0.13 per share for Q3 2026, with the current $1.12 stock price trading well below the average analyst target of $12.14.
Investors are primarily focused on clinical updates for the lead oncology asset, ateganosine (THIO), specifically enrollment milestones in the pivotal Phase 3 THIO-104 trial.
The company recently reached 65 patients in the THIO-104 study and remains on track to surpass 100 patients by year-end. These developments follow positive Phase 2 data showing a 90.5% disease control rate, which underpins the significant upside potential projected by analysts as the company expands its trial footprint into Europe.